Gowling WLG's Life Sciences team has acted for client Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics, Inc. in relation to an agreement with Amryt Pharma under which Amryt is granted the exclusive rights to LOJUXTA® (lomitapide®) hard capsules in certain European and Middle Eastern territories.

LOJUXTA® is currently approved by the European Commission and the agreement will allow Amryt to exclusively promote and distribute the medicine in the European Economic Area, Switzerland, Turkey and certain Middle Eastern and North African countries. The deal, was led by partner Patrick Duxbury. Gowling WLG worked closely with Vice President, EMEA Legal at Aegerion, Janet Kidd. The firm advised Aegerion on the drafting and negotiation of the transaction documents.

Patrick Duxbury commented: "We are delighted that this transaction between Amryt and Aergerion has been concluded. For Gowling WLG, the deal represents further indication of our extensive experience in the life sciences market."

As part of the agreement, Amryt will receive an exclusive license to promote and distribute the drug, paying Aegerion sales-related milestone payments and royalties on product sales in the territories. Amryt will also be responsible for ongoing regulatory and post-marketing obligations and commitments in support of the brand.

Assisting Patrick on the deal included Mathilda Davidson, Alice Stagg, James Barr and Bernardine Adkins.